ArticleBMC microbiology2026
Thermophilic bio-factory Bacillus sonorensis SS1 for superparamagnetic iron sulfide nanoparticles (FeSNPs) synthesis: in vitro and molecular modeling studies of anticancer activity.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An eco-friendly method lets the thermophilic Bacillus sonorensis SS1 synthesize superparamagnetic nano-sized iron sulfide particles (FeSNPs) as bio-factories. These clean and non-toxic FeSNPs have led to increased interest in using inorganic nanoparticles (NPs) in health materials and industrial products. The biosynthesized FeSNPs exhibited an average particle size of approximately 4.5 nm and a negative surface charge (- 16.8 ± 0.6 mV), indicating good colloidal stability. In vitro cytotoxicity evaluation using the MTT assay demonstrated concentration-dependent growth inhibition against five cancer cell lines (A549, HeLa, MCF-7, HepG2, and HCT-116), with IC₅₀ values ranging from 18 to > 100 µg/mL. The highest cytotoxic activity was observed against A549 (IC₅₀ = 18 µg/mL) and HeLa (IC₅₀ = 27 µg/mL) cells, and MCF-7 (IC₅₀ = 75 µg/mL) showed moderate sensitivity, while comparatively lower sensitivity was detected in HepG2 and HCT-116 cells (IC₅₀ value > 100 µg/mL). In contrast, normal peripheral blood mononuclear cells (PBMCs) exhibited minimal cytotoxicity, with an IC₅₀ value > 100 µg/mL, indicating selective anticancer activity of the FeSNPs. The molecular docking studies demonstrated that the FeSNPs exhibit a strong binding affinity to the active sites of Caspase-3, VEGFR, and Aurora-A. These interactions suggest that FeSNPs can effectively inhibit critical pathways involved in tumor growth, angiogenesis, and radiotherapy resistance. The biochemical validation confirmed these interactions, showing a 14.6-fold induction of active Caspase-3 (516.8 ± 20.1 pg/mL) in A549 cells. Additionally, FeSNPs exhibited potent inhibitory activity against VEGFR2 (IC₅₀ = 0.447 ± 0.019 µg/mL) and Aurora-A (IC₅₀ = 0.268 ± 0.012 µg/mL). These findings demonstrate the potential of FeSNPs as multifunctional agents capable of simultaneously triggering apoptosis and disrupting angiogenic and proliferative pathways. The findings focus on the potential of FeSNPs as versatile therapeutic agents in cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.